Bimekizumab Efficacy and Safety Through 3 Years in Patients with Hidradenitis Suppurativa: Results from the Phase 3 BE HEARD I&II Trials and Their Open-Label Extension BE HEARD EXT. J of Skin [Internet]. 2026 Mar. 10 [cited 2026 May 2];10(2):s762. Available from: https://skin.dermsquared.com/skin/article/view/4081